GPRC5D-Targeted Therapies in Relapsed Multiple Myeloma: Real-World Results and Community Practice Challenges : Episode 3
Patient Selection Factors for GPRC5D-Targeted Therapies
Panelists discuss how patient selection for GPRC5D-targeted therapies in the relapsed/refractory setting is guided by factors such as prior treatment history, including the number and types of previous therapies, with special consideration given to patients who have exhausted other options or shown resistance to earlier lines of treatment.
Video Player is loading.
EP: 1.GPRC5D-Targeted Therapies in Relapsed Multiple Myeloma
EP: 2.Real-World Efficacy of GPRC5D Bispecifics vs Clinical Trials
Now Viewing
EP: 3.Patient Selection Factors for GPRC5D-Targeted Therapies
EP: 4.Patient Subgroup Outcomes with GPRC5D Bispecifics
EP: 5.Biomarkers and Clinical Features Influencing GPRC5D Bispecific Initiation
EP: 6.Integration of GPRC5D-Targeted Therapies in RRMM Treatment
EP: 7.Prevalent Safety Concerns in Community Settings
EP: 8.Challenging Adverse Events with GPRC5D-Targeted Therapies
EP: 9.Long-Term Monitoring Protocols for Bispecific Therapy Complications
EP: 10.Proactive Steps for Mitigating GPRC5D Therapy Adverse Events
EP: 11.Logistical Barriers in Implementing GPRC5D-Targeted Therapies
EP: 12.Healthcare Resource Utilization Impact of GPRC5D-Targeted Therapies
EP: 13.Resources Needed for Enhanced Bispecific Implementation
EP: 14.Areas for Improvement in Real-World GPRC5D-Targeted Therapy Application
EP: 15.Future Impact of GPRC5D-Targeted Therapies on RRMM Treatment
EP: 16.Unmet Needs and Future Directions for GPRC5D Bispecific Therapy
- What factors guide your selection of patients for GPRC5D-targeted therapies in the relapsed/refractory setting?
- How do prior lines of therapy affect the selection process?
Recent Videos
Epithelioid Sarcoma: Histological Features and Differential Diagnoses
Epithelioid Sarcoma: Overview and Presentation
Leveraging PSMA PET Imaging in Posttreatment Response Assessment: Evolving Practices and Data Insights
Decision-Making Factors in Choosing Combination Therapies in EGFR-Mutated NSCLC
Evaluating Chemotherapy-Free vs Chemotherapy-Containing Combos in First-Line EGFR-Mutated NSCLC: Pros and Cons
Role of PSMA PET Imaging in Guiding Surgical Treatment Decisions in Prostate Cancer
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights from ACRO 2025
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
Precision Active Surveillance: Leveraging Genomic Testing and CCR Scores in Prostate Cancer Management
Using Genetic Information to Guide Precision Medicine and Personalized Treatment in Prostate Cancer: Expert Perspectives on an Evolving Landscape
Related Content
